Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF

被引:24
作者
Mooney, Leanne [1 ]
Hawkins, Nathaniel M. [2 ]
Jhund, Pardeep S. [1 ]
Redfield, Margaret M. [3 ]
Vaduganathan, Muthiah [4 ]
Desai, Akshay S. [4 ]
Rouleau, Jean L. [5 ]
Minamisawa, Masatoshi [4 ]
Shah, Amil M. [4 ]
Lefkowitz, Martin P. [6 ]
Zile, Michael R. [7 ]
Van Veldhuisen, Dirk J. [8 ]
Pfeffer, Marc A. [4 ]
Anand, Inder S. [9 ]
Maggioni, Aldo P. [10 ]
Senni, Michele [11 ,12 ]
Claggett, Brian L. [4 ]
Solomon, Scott D. [4 ]
McMurray, John J., V [1 ]
机构
[1] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
[2] Univ British Columbia, Div Cardiol, Vancouver, BC, Canada
[3] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA
[4] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[5] Univ Montreal, Inst Cardiol, Quebec City, PQ, Canada
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA
[8] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[9] Univ Minnesota, Minneapolis, MN USA
[10] ANMCO Res Ctr, Florence, Italy
[11] Papa Giovanni XXIII Hosp, Cardiovasc Dept, Bergamo, Italy
[12] Papa Giovanni XXIII Hosp, Cardiol Unit, Bergamo, Italy
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2021年 / 10卷 / 23期
关键词
chronic obstructive pulmonary disease; heart failure with preserved ejection fraction; right ventricle; sacubitril; valsartan; RIGHT-VENTRICULAR DYSFUNCTION; CLINICAL CHARACTERISTICS; PROGNOSTIC IMPLICATIONS; ARTERY PRESSURE; CO-MORBIDITIES; OUTCOMES; RATIONALE; TRIAL; COMORBIDITIES; HYPERTENSION;
D O I
10.1161/JAHA.121.021494
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Little is known about the impact of chronic obstructive pulmonary disease (COPD) in patients with heart failure with preserved ejection fraction (HFpEF). METHODS AND RESULTS: We examined outcomes in patients with heart failure with preserved ejection fraction, according to COPD status, in the PARAGON-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction) trial. The primary outcome was a composite of first and recurrent hospitalizations for heart failure and cardiovascular death. Of 4791 patients, 670 (14%) had COPD. Patients with COPD were more likely to be men (58% versus 47%; P<0.001) and had worse New York Heart Association functional class (class III/IV 24% versus 19%), worse Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores (69 versus 76; P<0.001) and more frequent history of heart failure hospitalization (54% versus 47%; P<0.001). The decrement in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores with COPD was greater than for other common comorbidities. Patients with COPD had echocardiographic right ventricular enlargement, higher serum creatinine (100 mu mol/L versus 96 mu mol/L) and neutrophil-to-lymphocyte ratio (2.7 versus 2.5), than those without COPD. After multivariable adjustment, COPD was associated with worse outcomes: adjusted rate ratio for the primary outcome 1.51 (95% CI, 1.25-1.83), total heart failure hospitalization 1.54 (95% CI, 1.24-1.90), cardiovascular death (adjusted hazard ratio [HR], 1.42; 95% CI, 1.10-1.82), and all-cause death (adjusted HR, 1.52; 95% CI, 1.25-1.84). COPD was associated with worse outcomes than other comorbidities and Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores declined more in patients with COPD than in those without. CONCLUSIONS: Approximately 1 in 7 patients with heart failure with preserved ejection fraction had concomitant COPD, which was associated with greater functional limitation and a higher risk of heart failure hospitalization and death.
引用
收藏
页数:19
相关论文
共 53 条
  • [1] Left ventricular volume and wall stress are linked to lung function impairment in COPD
    Alter, Peter
    Joerres, Rudolf A.
    Watz, Henrik
    Welte, Tobias
    Glaeser, Sven
    Schulz, Holger
    Bals, Robert
    Karch, Annika
    Wouters, Emiel F. M.
    Vestbo, Jorgen
    Young, David
    Vogelmeier, Claus F.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 261 : 172 - 178
  • [2] Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease
    Arcasoy, SM
    Christie, JD
    Ferrari, VA
    Sutton, MS
    Zisman, DA
    Blumenthal, NP
    Pochettino, A
    Kotloff, RM
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (05) : 735 - 740
  • [3] Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial)
    Boehm, Michael
    Robertson, Michele
    Ford, Ian
    Borer, Jeffrey S.
    Komajda, Michel
    Kindermann, Ingrid
    Maack, Christoph
    Lainscak, Mitja
    Swedberg, Karl
    Tavazzi, Luigi
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2015, 116 (12) : 1890 - 1897
  • [4] Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction
    Bosch, Lena
    Lam, Carolyn S. P.
    Gong, Lingli
    Chan, Siew Pang
    Sim, David
    Yeo, Daniel
    Jaufeerally, Fazlur
    Leong, Kui Toh Gerard
    Ong, Hean Yee
    Ng, Tze Pin
    Richards, Arthur Mark
    Arslan, Fatih
    Ling, Lieng H.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (12) : 1664 - 1671
  • [5] The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease
    Boudestein, Laura C. M.
    Rutten, Frans H.
    Cramer, Maarten J.
    Lammers, Jan Willem J.
    Hoes, Arno W.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (12) : 1182 - 1188
  • [6] Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure
    Braunstein, JB
    Anderson, GF
    Gerstenblith, G
    Weller, W
    Niefeld, M
    Herbert, R
    Wu, AW
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (07) : 1226 - 1233
  • [7] Descriptors of dyspnea by patients with chronic obstructive pulmonary disease versus congestive heart failure
    Caroci, AD
    Lareau, SC
    [J]. HEART & LUNG, 2004, 33 (02): : 102 - 110
  • [8] The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: Rationale and design
    Carson, P
    Massie, BM
    McKelvie, R
    McMurray, J
    Komajda, M
    Zile, M
    Ptaszynska, A
    Frangin, G
    [J]. JOURNAL OF CARDIAC FAILURE, 2005, 11 (08) : 576 - 585
  • [9] Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study
    Caruana, L
    Petrie, MC
    Davie, AP
    McMurray, JJV
    [J]. BRITISH MEDICAL JOURNAL, 2000, 321 (7255) : 215 - 218
  • [10] How do patients with heart failure with preserved ejection fraction die?
    Chan, Michelle M. Y.
    Lam, Carolyn S. P.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (06) : 604 - 613